SG11201907927SA - Binding molecules that specifically bind to tau - Google Patents

Binding molecules that specifically bind to tau

Info

Publication number
SG11201907927SA
SG11201907927SA SG11201907927SA SG11201907927SA SG 11201907927S A SG11201907927S A SG 11201907927SA SG 11201907927S A SG11201907927S A SG 11201907927SA SG 11201907927S A SG11201907927S A SG 11201907927SA
Authority
SG
Singapore
Prior art keywords
international
archimedesweg
leiden
binding molecules
pct
Prior art date
Application number
Other languages
English (en)
Inventor
Jaroslaw Juraszek
Constantin Apetri
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of SG11201907927SA publication Critical patent/SG11201907927SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SG11201907927S 2017-03-28 2018-03-27 Binding molecules that specifically bind to tau SG11201907927SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17163425 2017-03-28
PCT/EP2018/057770 WO2018178077A1 (en) 2017-03-28 2018-03-27 Binding molecules that specifically bind to tau

Publications (1)

Publication Number Publication Date
SG11201907927SA true SG11201907927SA (en) 2019-10-30

Family

ID=58448491

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907927S SG11201907927SA (en) 2017-03-28 2018-03-27 Binding molecules that specifically bind to tau

Country Status (10)

Country Link
US (1) US11028157B2 (ru)
EP (1) EP3601335A1 (ru)
JP (1) JP7109467B2 (ru)
KR (1) KR20190133191A (ru)
CN (1) CN110418804A (ru)
AU (1) AU2018241857A1 (ru)
CA (1) CA3056517A1 (ru)
EA (1) EA201992281A1 (ru)
SG (1) SG11201907927SA (ru)
WO (1) WO2018178077A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970453B1 (en) 2013-03-13 2019-12-04 Prothena Biosciences Limited Tau immunotherapy
WO2017191559A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
UA124148C2 (uk) 2016-05-02 2021-07-28 Протена Біосайенсіс Лімітед Антитіла, що розпізнають тау
WO2018152359A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
BR112019022906A2 (pt) 2017-05-02 2020-05-26 Prothena Biosciences Limited Anticorpos que reconhecem tau
SG11202108414UA (en) 2019-03-03 2021-08-30 Prothena Biosciences Ltd Antibodies recognizing tau
GB201909393D0 (en) 2019-06-28 2019-08-14 Gen2 Neuroscience Ltd Tau epitope and binding molecules
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60043273D1 (de) 1999-04-15 2009-12-17 Crucell Holland Bv Verwendung von Rekombinanten Proteinen in Menschlichen Zellen
ES2686550T3 (es) * 2010-10-11 2018-10-18 Biogen International Neuroscience Gmbh Anticuerpos anti-tau humanos
EP2701743A4 (en) 2011-04-27 2015-08-19 Univ Northwestern SELECTIVE ANTIBODIES FOR TAU PATHOLOGICAL DIMERS AND PRE-FIBRILLARY TAU PATHOLOGICAL OLIGOMERS AND THEIR USE IN THE TREATMENT, DIAGNOSIS AND MONITORING OF TAUOPATHIES
UA115657C2 (uk) 2011-09-19 2017-12-11 Аксон Ньюросайєнс Сє Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла
ZA201608812B (en) * 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
KR20170023151A (ko) * 2014-06-26 2017-03-02 얀센 백신스 앤드 프리벤션 비.브이. 미세소관-연관 단백질 타우에 특이적으로 결합하는 항체 및 항원-결합 단편
RS61431B1 (sr) 2014-11-19 2021-03-31 Axon Neuroscience Se Humanizovana antitela na tau u alchajmerovoj bolesti

Also Published As

Publication number Publication date
JP2020511976A (ja) 2020-04-23
EA201992281A1 (ru) 2020-02-13
AU2018241857A1 (en) 2019-09-19
US11028157B2 (en) 2021-06-08
JP7109467B2 (ja) 2022-07-29
KR20190133191A (ko) 2019-12-02
EP3601335A1 (en) 2020-02-05
CN110418804A (zh) 2019-11-05
WO2018178077A1 (en) 2018-10-04
US20210122810A1 (en) 2021-04-29
CA3056517A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
SG11201907927SA (en) Binding molecules that specifically bind to tau
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201811432WA (en) Rna for cancer therapy
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201807912SA (en) Vaccine against rsv
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201908919XA (en) Combination therapies targeting pd-1, tim-3, and lag-3
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201403106SA (en) Anti-phf-tau antibodies and their uses
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201807523PA (en) Ilt7 binding molecules and methods of using the same
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201803692PA (en) Anti-5t4 antibodies and antibody-drug conjugates
SG11201907208XA (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201810801QA (en) Brain delivery protein
SG11201807062RA (en) Anti-tnfalpha-antibodies and functional fragments thereof
SG11201806622PA (en) Egfl6 specific monoclonal antibodies and methods of their use
SG11201900132QA (en) Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy